INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of “Reduce” by Brokerages

Shares of INmune Bio, Inc. (NASDAQ:INMB) have received an average rating of “Reduce” from the five analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.00.

Separately, Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

INmune Bio Stock Up 5.1%

Shares of INMB opened at $1.33 on Friday. The business’s fifty day moving average is $1.51 and its 200 day moving average is $1.74. INmune Bio has a 12-month low of $1.21 and a 12-month high of $11.64. The stock has a market cap of $35.35 million, a P/E ratio of -0.63 and a beta of 0.77.

Institutional Investors Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently made changes to their positions in INMB. Quadrature Capital Ltd bought a new position in INmune Bio in the 4th quarter valued at about $26,000. Intech Investment Management LLC bought a new stake in INmune Bio during the 2nd quarter worth approximately $26,000. Cary Street Partners Financial LLC purchased a new stake in shares of INmune Bio in the third quarter worth approximately $29,000. Independent Advisor Alliance purchased a new stake in shares of INmune Bio in the third quarter worth approximately $30,000. Finally, Squarepoint Ops LLC bought a new position in shares of INmune Bio in the third quarter valued at approximately $30,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.